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Objectives. We sought to determine whether the rapid bedside
assay for troponin T identified patients at risk for a more
complicated hospital stay and a higher rate of adverse clinical
events.
Background. In patients with an acute coronary syndrome, the
amount of cardiac-specific troponin T released bears a stoichio-
metric relation to the extent of myocardial damage.
Methods. In 597 patients with unstable angina or non–Q wave
myocardial infarction participating in the Thrombolysis in Myo-
cardial Infarction (TIMI) 11A substudy, a rapid bedside assay
and simultaneous quantitative serum measurement for troponin
T were obtained at enrollment.
Results. The composite end point of the sum of death, nonfatal
myocardial infarction or recurrent ischemia through day 14
occurred in 33.6% of patients with a positive assay compared with
only 22.5% of patients with a negative assay (p 5 0.01). Those
patients in whom the rapid assay became positive in <210 min had
the highest mortality rate of 4.2% through day 14 compared with
1.1% in those patients who had either a late-appearing positive
assay (>10 min) or a negative assay. The duration of hospital stay
in the 116 patients (19%) with a positive rapid assay at enrollment
was a median of 5 days compared with only 3 days in the 481
patients (81%) with a negative rapid assay at enrollment (p 5
0.002).
Conclusions. A positive rapid assay for troponin T at presen-
tation identifies those patients at risk for higher rates of adverse
clinical events and longer, more complicated hospital stays.
Stratification of patients by time to development of a positive
rapid assay identifies those patients at highest mortality risk.
(J Am Coll Cardiol 1998;31:326–30)
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Several studies have shown that patients with unstable angina
or non–Q wave myocardial infarction (NQMI) are a hetero-
geneous group with a wide range of risks of adverse clinical
outcomes (1,2). For example, patients .65 years of age are
more than twice as likely to experience death or nonfatal
myocardial infarction (MI) within 6 weeks of presentation
compared with patients ,65 years of age (2). The extent of
myocardial necrosis sustained at the time of presentation with
an acute coronary syndrome is an important determinant of
the risk of adverse clinical outcome (3,4). The classic serum
cardiac markers of myocardial damage, creatine kinase and its
MB isoenzyme (CK-MB), suffer from a lack of specificity as
well as a lack of sufficient sensitivity for detection of small
amounts of myocardial necrosis (i.e., microinfarction) (5,6). In
contrast, cardiac-specific troponin T (cTnT) has a greater
specificity for myocardial necrosis than CK-MB and is also
more sensitive to lesser degrees of myocardial necrosis (7–9).
The amount of cTnT released into the blood stream bears a
close stoichiometric relation to the amount of myocardial
damage (10).
Detection of serum cTnT levels above the reference inter-
val, using a commercially available quantitative enzyme immu-
noassay, identifies a subgroup of patients at increased risk of
adverse clinical outcomes (11). The development by Katus and
co-workers of a hand-held, rapid bedside assay enables clini-
cians to measure cTnT without the inherent delay of transport-
ing specimens to a central chemistry laboratory (12). Previous
evaluations of the rapid assay focused predominantly on its
ability to diagnose MI when studied in a single, dedicated
research center (12). The objectives of this study were 1) to
determine if the rapid assay for cTnT could identify patients
with unstable angina or NQMI who are at risk for a higher rate
of adverse clinical events and a more complicated hospital stay;
2) to determine whether the time to positivity of the assay
could be used as an alternative method for estimating cTnT
measurements and would be predictive of mortality risk; and 3)
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to determine whether the rapid assay was a useful bedside tool
that could be used in a widespread field application across
multiple clinical centers.
Methods
We evaluated the prognostic potential of the Cardiac T
Rapid Assay (Boehringer Mannheim Corp.) in the 45 centers
participating in the previously reported Thrombolysis in Myo-
cardial Infarction (TIMI) 11A trial (13). This was an open-
label, dose-ranging study of the low molecular weight heparin
preparation enoxaparin in patients with unstable angina and
NQMI. Patients were eligible for enrollment in TIMI 11A if a
qualifying episode of ischemic discomfort occurred within the
preceding week and was characterized by either rest angina
lasting $5 min, new-onset angina or increased severity of a
previously stable anginal pattern. Major exclusion criteria
included an evolving Q wave MI, coronary artery bypass graft
surgery (CABG) within the previous 2 months and contrain-
dications to anticoagulation (13). Patients were considered to
have had a NQMI at enrollment if CK-MB measurements at
the enrolling site were above normal (and $3% of total CK) at
baseline or ;8 h after enrollment, or if CK-MB measurements
were elevated at the 16-h sample and no ischemic discomfort
for $30 min occurred between enrollment and the 16-h
sample.
The cTnT substudy protocol specified that a rapid assay
should be performed at enrollment along with a simulta-
neously drawn serum specimen for quantitative assessment of
cTnT. Clinical events assessed in the group undergoing cTnT
testing included 1) death (all-cause mortality); 2) recurrent
nonfatal MI (defined by [re]elevation of CK-MB levels above
normal [fivefold elevation after CABG] and/or new Q waves or
left bundle branch block on the electrocardiogram [ECG]);
and 3) recurrent ischemic discomfort. The composite end point
noted previously was selected for the cTnT substudy based on
previous observations that patients with unstable angina or
NQMI presenting with elevated cTnT levels are at increased
risk for multiple adverse clinical events, including mortality
and recurrent infarction, and also undergo revascularization
procedures more frequently (11). This suggests that patients
with elevated cTnT at presentation have sufficient coronary
artery disease to place them at risk not only for an initial
episode of myocardial necrosis but also for repeated bouts of
myocardial ischemia and infarction.
Rapid assay for cTnT. The test is performed by placing 150
ml of whole blood in the specimen well, where cTnT reacts with
two monoclonal antibodies (12,14). The cTnT in the patient’s
blood binds to the two antibodies and forms a sandwich that
flows along a glass-fiber fleece toward the read zone. The
immune complexes are immobilized in the read zone by an
interaction between streptavidin (bound to the cellulose ni-
trate membrane) and the biotinylated antibody. This ultimately
leads to production of a purplish-red line in the read zone. The
intensity of the color and the speed with which it develops
correlate with the concentration of cTnT in the patient’s blood
(12). Another red line develops in an on-board control area
where unreacted gold-labeled antibodies react with cTnT
bound to the membrane. The rapid assay is considered positive
if by 20 min two red lines form, even if the patient line appears
only faintly. The detection limit of this version of the rapid
assay is 0.2 ng/ml of cTnT.
The protocol specified that the rapid assay be read locally
by clinical personnel not directly involved in the care of
patients enrolled in TIMI 11A and the results not be used in
clinical decision-making. The test was read as either positive or
negative. Positive results were categorized as to whether the
red line in the patient area appeared within #10 min or
.10 min. Patients who had a negative rapid assay were
categorized as to whether they presented #6 h or .6 h from
the onset of ischemic discomfort.
Quantitative assay for cTnT. Blood specimens were drawn
at presentation (simultaneous with rapid assay) and centri-
fuged locally, and the serum was extracted. Samples were
stored at 220°C until shipment to the core laboratory, where
they were analyzed for cTnT on the ES-300 immunoanalyzer
using the Enzymun assay. This assay uses complementary dual
cardiac-specific monoclonal antibodies and has a detection
limit of 0.01 ng/ml (15).
Statistical analysis. The results of the rapid assay and
quantitative assay for cTnT were merged with the clinical data
base for TIMI 11A at the Data Coordinating Center for the
main trial (Covance, Princeton, New Jersey), where the anal-
yses were performed. With regard to baseline characteristics
and clinical outcomes, patients who had a positive rapid assay
were compared with patients who had a negative rapid assay,
using the Student t test for continuous variables and the
chi-square test for dichotomous variables. Plots depicting time
to clinical events were constructed using the Kaplan-Meier
method, and curves were compared using the log-rank test.
The quantitative cTnT results in various patient groups strat-
ified by the results of the rapid assay were compared using the
Kruskal-Wallis test. All statistical comparisons were two-
tailed, and p , 0.05 was considered statistically significant.
Results
Baseline characteristics. Of the 630 patients enrolled in
TIMI 11A between July 1995 and January 1996, 597 (95%) had
rapid assays performed and participated in the cTnT substudy.
Of the 597 patients with rapid assays performed at enrollment,
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CK-MB 5 creatine kinase, MB isoenzyme
cTnT 5 cardiac-specific troponin T
ECG 5 electrocardiogram
MI 5 myocardial infarction
NQMI 5 non–Q wave myocardial infarction
TIMI 5 Thrombolysis in Myocardial Infarction
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538 (90%) had a simultaneous quantitative measurement of
cTnT in the core laboratory. The rapid assay at enrollment was
positive by 20 min in 116 patients and by 10 min in 48 patients,
and was negative in 481 patients. The two groups of patients
stratified by a positive or negative rapid assay by 20 min at
enrollment had similar baseline characteristics and were also
representative of the entire group enrolled in the TIMI 11A
trial (Table 1). However, the interval between the onset of
ischemic discomfort and performance of the rapid assay was
significantly shorter in patients with a negative assay (p ,
0.001).
Clinical events. The composite end point of the sum of
death, nonfatal MI or recurrent ischemia through day 14
occurred in 33.6% of patients with a positive assay compared
with 22.5% of patients with a negative assay (p 5 0.01 by the
chi-square test). Kaplan-Meier plots of the time to the first of
any of the events noted earlier revealed an early separation by
3 days and a persistent separation of the curves by day 14 (p 5
0.01 by the log-rank test) (Fig. 1).
The duration of hospital stay was a median of 5 days
(interquartile range 3 to 8) in patients with a positive rapid
assay, but 3 days (interquartile range 2 to 5) in patients with a
Table 1. Baseline Characteristics
Troponin T Substudy
(n 5 597)
Main TIMI
11A Trial
(n 5 630)
Positive Rapid
Assay by 20 min
(n 5 116)
Negative
Rapid Assay
(n 5 481)
Age (yr) 65 (55, 71) 64 (54, 71) 64 (54, 71)
Gender
Male 80 (69) 298 (62) 399 (63)
Female 36 (31) 183 (38) 231 (37)
Race
White 100 (86) 384 (80) 512 (81)
Other 16 (14) 97 (20) 118 (19)
Diabetes 39 (34) 157 (33) 203 (32)
Current smoker 34 (29) 122 (26) 163 (26)
Hypertension 74 (64) 287 (60) 375 (60)
Previous cardiac history
Angina 74 (64) 351 (73) 445 (71)
Previous angiogram with $50% stenosis 55 (48) 275 (59) 348 (55)
PTCA 24 (21) 157 (33) 194 (31)
CABG 28 (24) 122 (25) 158 (25)
MI 52 (45) 175 (37) 242 (38)
Medications before enrollment
ASA 102 (88) 383 (80) 512 (81)
IV nitrates 56 (48) 98 (20) 160 (25)
Beta-blocker 62 (53) 230 (48) 304 (48)
IV heparin 80 (69) 195 (41) 286 (45)
Characteristics of presenting illness
Time since qualifying pain (h) 32 (14, 62) 14 (6, 31)* 16 (7, 38)
Non–Q wave MI (CK-MB criteria) 19 (16) 28 (6)* 48 (8)
*p , 0.001 for comparison between groups with a positive versus negative rapid assay. For continuous variables the
values shown indicate the median (25th, 75th percentiles); for dichotomous variables the values indicate the number (%)
of patients with a given finding. ASA 5 acetylsalicyclic acid (aspirin); CABG 5 coronary artery bypass graft surgery;
CK-MB 5 creatine kinase, MB isoenzyme; IV 5 intravenous; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty.
Figure 1. Kaplan-Meier plot of time to first adverse clinical event
(death, nonfatal MI or recurrent ischemia) through day 14 in patients
(Pts) with a positive or a negative rapid assay for cTnT. The distribu-
tion of clinical events in the two groups is shown in the tabulation
below:
Event Pos (n 5 116) Neg (n 5 481)
Death 2 (1.7%) 7 (1.5%)
MI 2 (1.7%) 8 (1.7%)
Rec isch 35 (30.2%) 93 (19.3%)
Any 39 (33.6%) 108 (22.5%)
Neg 5 negative rapid assay; Pos 5 positive rapid assay; Rec isch 5 recurrent
ischemia.
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negative rapid assay at enrollment (p 5 0.002). The composite
end point of death, nonfatal MI, recurrent ischemia and the
performance of percutaneous transluminal coronary angio-
plasty or CABG through hospital discharge occurred in 50.9%
of patients with a positive rapid assay at enrollment, but in
37.8% of patients with a negative rapid assay (p 5 0.01).
Correlation of rapid assay with quantitative cTnT and
mortality. Among the 538 patients with both a quantitative
assessment and rapid assay for cTnT at enrollment, 110 (20%)
and 428 (80%) had quantitative cTnT values $0.2 ng/ml and
,0.2 ng/ml, respectively. The rapid assay for cTnT was positive
by 20 min in 107 (20%) and negative in 431 (80%) patients. Of
the 431 patients with a negative rapid assay, 24 (6%) had a
quantitative cTnT value $0.2 ng/ml (median 0.31 [range 0.23
to 0.43]). A rapid assay by 20 min had a sensitivity of 78% and
a specificity of 95% for detection of a quantitative cTnT value
$0.2 ng/ml.
As depicted in Figure 2A, those patients who had a positive
rapid assay in #10 min had a median cTnT level of 2.3
ng/ml(range 1.2 to 5.0) compared with 0.4 ng/ml (range 0.1 to
1.0) when the assay was positive in .10 min. Patients who had
a negative rapid assay but who presented both .6 h from the
onset of chest pain and #6 h from the onset of chest pain had
median cTnT levels of 0.01 ng/ml. The differences in the cTnT
levels among the four groups of patients shown in Figure 2A
were significant at p , 0.001.
The mortality rate through 14 days in the patients with a
quantitative cTnT level $0.2 ng/ml was 2.7% compared with
1.2% in patients with a quantitative cTnT level ,0.2 ng/ml.
However, those patients who had a positive rapid assay in
#10 min had the highest mortality rate of 4.2% through day 14
(Fig. 2B). There were no deaths in the group with a positive
assay in .10 min. The mortality rate in the patients with a
negative assay who presented .6 h from the onset of pain was
1.4% compared with 1.0% in patients with a negative assay
presenting within 6 h of pain. The mortality rate in those
patients who had either a late-appearing positive rapid assay
(.10 min) or a negative assay, collectively, was 1.1%.
Comparison with CK-MB. Of the total of 597 patients
participating in the cTnT substudy, 47 (8%) were diagnosed as
having a NQMI at enrollment by CK-MB criteria as compared
with 116 (19%) who had a positive rapid assay for cTnT. The
14-day mortality rate was 2.1% in the patients diagnosed as
having NQMI by CK-MB compared with 1.7% in those with a
positive rapid assay by 20 min and 4.2% in those with a positive
rapid assay in #10 min.
Discussion
Previous studies in patients with unstable angina or NQMI,
using quantitative measurements of cardiac-specific troponins
in specialized core laboratories, have shown a gradient of risk
for adverse clinical events with detection of increasing quanti-
ties of these proteins in the blood at the time of clinical
presentation (11,16). The prognostic information conveyed by
Figure 2. Quantitative cTnT and mortality findings stratified by results
of rapid assay at study enrollment. In both the top and bottom graphs,
four groups of patients are shown: positive (Pos) rapid assay #10 min;
positive rapid assay .10 min; negative (Neg) rapid assay but presen-
tation .6 h from onset of discomfort; and negative rapid assay but
presentation #6 h from onset of ischemic discomfort. Top, Simulta-
neously measured quantitative serum cTnT levels (median [25, 75
percentiles]) were highest in patients with an early positive rapid assay
and were progressively lower in the other patient groups depicted. p ,
0.0001 by the Kruskal-Wallis test. Bottom, Mortality through 14 days
was highest in the patients with an early positive rapid assay compared
with the patients with a late positive rapid assay or negative rapid assay
at enrollment. Note: The total number of patients in each of the four
groups is different in the top and bottom graphs because not all
patients with a rapid assay had a simultaneous quantitative cTnT
measurement.
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measurement of the cardiac troponins was independent of
demographic characteristics and ECG findings (11,16).
Our study demonstrates that patients with a positive rapid
assay are at higher risk of adverse clinical events and longer,
more complicated hospital stays. By using the speed of color
development of the red line in the read zone of the rapid assay,
it is possible to arrive at a semiquantitative estimate of the
concentration of cTnT in a patient’s blood. Importantly, our
findings show for the first time that the time to positivity of the
rapid assay is predictive of mortality risk. Prognostication using
the time to positivity of the rapid assay compared favorably
with simple dichotomization of quantitative cTnT measure-
ments at a cutoff level of 0.2 ng/ml, as well as diagnosis of
NQMI by conventional CK-MB criteria, with 14-day mortality
rates tending to be highest in those with an early (#10 min)
positive rapid assay. The absolute mortality rates and the
gradient of mortality risk depicted in Figure 2B are nearly
identical to those reported by the Fragmin During Instability in
Coronary Artery Disease (FRISC) investigators who stratified
a group of patients with unstable angina according to quanti-
tative cTnT measurements in a core laboratory (17). The data
contained in the FRISC report show a 14-day mortality rate of
;4% in patients with the highest quintile of cTnT ($2.12
ng/ml) and #1% in patients with the lowest quintiles of cTnT
(,0.62 ng/ml). Finally, our evaluation of the rapid assay has
demonstrated it to be a useful prognostic tool when tested in a
widespread field application in 45 separate centers.
Clinical implications. The rapid assay is a reliable, conve-
nient alternative method for bedside assessment of the level of
cTnT in a patient’s blood at the time of presentation with an
acute coronary syndrome. As shown in our report, not only
does the rapid assay extend the capability of measuring cTnT
to the site where medical care is being delivered, but it also
provides clinicians with a tool for prognostication at the
patient’s bedside. The data in Figure 2 indicate that the rapid
assay for cTnT conveys the same diagnostic and prognostic
information provided by a quantitative test for cTnT. In the
context of other reports documenting the diagnostic and
prognostic efficiency of the rapid assay in patients with ST
segment elevation, our study extends the evidence that the
rapid assay for cTnT is useful across the entire spectrum of
acute coronary syndromes, and may be helpful to clinicians
when assigning a patient to an intensive care setting versus a
stepdown unit or another less costly facility (14,18,19). Of note,
negative rapid assays must be analyzed with reference to the
clinical circumstances under which they were obtained. As with
all assays of serum cardiac markers, the rapid assay for cTnT
should be interpreted in the context of the number of hours
elapsed from the onset of ischemic discomfort (14). Because of
the kinetics of cTnT release from the myocardium, patients
presenting ,6 h from the onset of symptoms may have a
negative rapid assay (Table 1), yet be at risk for adverse clinical
events (Fig. 2B).
Use of the rapid assay for cTnT eliminates the delay in
turnaround time, even in hospitals with chemistry laboratories
offering quantitative cTnT measurements on an urgent basis. It
also provides clinicians with a simple means for measuring
cTnT, even if a quantitative test is not available in their
hospital, and makes such assessment possible in other settings
such as the physician’s office, free-standing clinic or ambu-
lance. Technologic improvements, including subsequent gen-
erations of the rapid assay with an even lower detection limit
(0.08 ng/ml) and which can be read within 15 min, are
anticipated to increase the clinical appeal of this device even
further.
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